These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14567637)

  • 21. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic and kinetic investigation of adefovir dipivoxil during phase transformation.
    An JH; Choi GJ; Kim WS
    Int J Pharm; 2012 Jan; 422(1-2):185-93. PubMed ID: 22079719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate).
    Murnane D; Martin GP; Marriott C
    J Pharm Biomed Anal; 2006 Mar; 40(5):1149-54. PubMed ID: 16280225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using gold nanoparticles as probe for detection of salmeterol xinafoate by resonance Rayleigh light scattering.
    Bi S; Wang T; Wang Y; Zhao T; Zhou H
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 135():1074-9. PubMed ID: 25173524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing an environmentally benign process for the production of microparticles: amphiphilic crystallization.
    Murnane D; Marriott C; Martin GP
    Eur J Pharm Biopharm; 2008 May; 69(1):72-82. PubMed ID: 18082385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment.
    Amore E; Manca ML; Ferraro M; Valenti D; La Parola V; Di Vincenzo S; Gjomarkaj M; Giammona G; Bondì ML; Pace E
    Int J Pharm; 2019 May; 562():351-358. PubMed ID: 30935915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of sample preparation method on quantification of polymorphs using PXRD.
    Alam S; Patel S; Bansal AK
    Pharm Dev Technol; 2010; 15(5):452-9. PubMed ID: 19842910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy.
    Li Y; Chow PS; Tan RB
    Int J Pharm; 2011 Aug; 415(1-2):110-8. PubMed ID: 21645601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A quantitative model to evaluate solubility relationship of polymorphs from their thermal properties.
    Mao C; Pinal R; Morris KR
    Pharm Res; 2005 Jul; 22(7):1149-57. PubMed ID: 16028016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase transformations undergone by Triton X-100 probed by differential scanning calorimetry and dielectric relaxation spectroscopy.
    Merino EG; Rodrigues C; Viciosa MT; Melo C; Sotomayor J; Dionísio M; Correia NT
    J Phys Chem B; 2011 Nov; 115(43):12336-47. PubMed ID: 21928821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of protection by inhaled salmeterol in exercise-induced asthma.
    Anderson SD; Rodwell LT; Du Toit J; Young IH
    Chest; 1991 Nov; 100(5):1254-60. PubMed ID: 1682113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal doping aided by rapid expansion of supercritical solutions.
    Vemavarapu C; Mollan MJ; Needham TE
    AAPS PharmSciTech; 2002; 3(4):E29. PubMed ID: 12916923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells.
    Akabane H; Murata M; Kubota M; Takashima E; Tanaka H; Inagaki N; Horiba M; Nagai H
    Allergol Int; 2006 Dec; 55(4):387-93. PubMed ID: 17130681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
    Manchee GR; Eddershaw PJ; Ranshaw LE; Herriott D; Park GR; Bayliss MK; Tarbit MH
    Drug Metab Dispos; 1996 May; 24(5):555-9. PubMed ID: 8723736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of reversible polymorphic phase transitions by thermal analysis.
    Shah AC; Britten NJ
    J Pharm Pharmacol; 1987 Sep; 39(9):736-8. PubMed ID: 2890741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy.
    Islam N; Stewart P; Larson I; Hartley P
    J Pharm Sci; 2005 Jul; 94(7):1500-11. PubMed ID: 15924347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
    Busse W; Nelson H; Wolfe J; Kalberg C; Yancey SW; Rickard KA
    J Allergy Clin Immunol; 1999 Jun; 103(6):1075-80. PubMed ID: 10359889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.